Evidence map›Paper›PMID 30120238›Full record

ArticleNature communications2018

Conditional control of fluorescent protein degradation by an auxin-dependent nanobody.

Katrin Daniel, Jaroslav Icha, Cindy Horenburg, Doris Müller, Caren Norden, Jörg Mansfeld

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 125 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Molecular tags for electron cryo-tomography.Emerging topics in life sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Elucidating the Role ofBiomolecules · 2025
    Article
  11. Review
  12. Journal of medicinal chemistry · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Katrin DanielCell Cycle, Biotechnology Center, Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany.
Jaroslav IchaMax Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstraße 108, 01307, Dresden, Germany.ORCID http://orcid.org/0000-0002-0657-3278
Cindy HorenburgCell Cycle, Biotechnology Center, Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany.
Doris MüllerCell Cycle, Biotechnology Center, Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany.
Caren NordenMax Planck Institute of Molecular Cell Biology and Genetics, Pfotenhauerstraße 108, 01307, Dresden, Germany. norden@mpi-cbg.de.ORCID http://orcid.org/0000-0001-8835-1451
Jörg MansfeldCell Cycle, Biotechnology Center, Technische Universität Dresden, Tatzberg 47-49, 01307, Dresden, Germany. joerg.mansfeld@tu-dresden.de.ORCID http://orcid.org/0000-0002-0562-8206
Technische Universität Dresden · DEMax Planck Institute of Molecular Cell Biology and Genetics · DEUniversity of Turku · FI

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) MA 5831/1-1EC | European Research Council (ERC) 680042
6 · The paper itself

Abstract

The conditional and reversible depletion of proteins by auxin-mediated degradation is a powerful tool to investigate protein functions in cells and whole organisms. However, its wider applications require fusing the auxin-inducible degron (AID) to individual target proteins. Thus, establishing the auxin system for multiple proteins can be challenging. Another approach for directed protein degradation are anti-GFP nanobodies, which can be applied to GFP stock collections that are readily available in different experimental models. Here, we combine the advantages of auxin and nanobody-based degradation technologies creating an AID-nanobody to degrade GFP-tagged proteins at different cellular structures in a conditional and reversible manner in human cells. We demonstrate efficient and reversible inactivation of the anaphase promoting complex/cyclosome (APC/C) and thus provide new means to study the functions of this essential ubiquitin E3 ligase. Further, we establish auxin degradation in a vertebrate model organism by employing AID-nanobodies in zebrafish.

Indexed as

ProteolysisAnaphase-Promoting Complex-CyclosomeAnimalsCell CompartmentationGreen Fluorescent ProteinsHeLa CellsHumansIndoleacetic AcidsKineticsLysineRecombinant Fusion ProteinsSingle-Domain AntibodiesZebrafishAnaphase-Promoting Complex-CyclosomeGreen Fluorescent ProteinsIndoleacetic AcidsLysineRecombinant Fusion ProteinsSingle-Domain Antibodies

Identifiers

PMID30120238
PMCPMC6098157
OpenAlexW2951829327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.